Sign in
Taking people in United StatesPhase 1/2

A Phase I/II Trial of JR-446 in Mucopolysaccharidosis Type IIIB (MPS IIIB)

Key facts

Who runs it
JCR Pharmaceuticals Co., Ltd.
Where
Fairfax, Oakland, and Pittsburgh, United StatesSee the 3 sitesAlso in 2 other countries, 2 sites
Status
Recruiting
Phase
Phase 1/2
People taking part
12 people, planned
Started
9 Sept 2026
Expected to end
30 Sept 2028
Type of study
Interventional
Treatments tested
  • JR-446
Record updated
21 September 2026

Who can take part

Age
Up to 5 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Patients with confirmed MPS IIIB with a phenotype of MPS IIIB that is not classified as slowly progressive (i.e., not attenuated)
  • A chronological age <6 years
  • Ability to complete and achieve a Standard score ≥55, using either Bailey Scale of Infant Development-4 (BSID-4) Cognitive domain or Kaufman Assessment Battery for Children-II (KABC-II) Non-Verbal Index, whichever tool is most appropriate for the participant's chronological age

Who cannot take part

  • A participant who has received any other investigational drug product (including but not limited to, tralesinidase alfa enzyme replacement therapy [TA-ERT], Genistein, KINERET [anakinra], ambroxol, miglustat) within 4 months (or 5 half-lives, whichever is longer) before the time of providing informed consent
  • A participant who has received gene therapy treatment or hematopoietic stem cell transplantation (HSCT) with successful engraftment
  • A participant who has a medical condition or extenuating circumstance that, in the opinion of the principal investigator or sub-investigator, might compromise the participant's ability to comply with protocol requirements, the participant's well-being or safety, or the interpretability of the participant's clinical data
  • Serious drug allergy or hypersensitivity to any components of JR-446 or medications likely prescribed during the trial
  • A participant has a history of bleeding disorder or current use of medications that, in the opinion of the investigator, place them at risk of bleeding following lumbar puncture
  • A patient with recurrent epileptic seizures not adequately controlled with anti-seizure medication, and which, in the clinical judgment of the principal investigator, would preclude safe participation in the trial
  • Serology consistent with human immunodeficiency virus (HIV) exposure or consistent with active hepatitis B (HepB) or hepatitis C (HepC) infection
  • Contraindication for lumbar puncture or MRI
  • A participant/family, who, in the opinion of the investigator, may not be able to comply with protocol requirements and cooperate fully with the trial assessments, procedures, and scheduling for JR-446 IMP dose administrations
  • Study participants for whom informed consent is unable to be provided by a parent or legal guardian; or when applicable for a study participant who is unable to provide assent with respect to study participation in conjunction with parental or legal guardian consent for participation on study; The above information is not intended to contain all considerations relevant to a patient's potential participation in this clinical trial

Where in United States

Also in 2 other countries, 2 sites

  • Lysosomal and Rare Disorders Research and Treatment Center (LDRTC)Fairfax, United StatesContact: Ozlem Goker-AlpanNot yet recruiting
  • Children's Hospital Oakland Research Institution, Attn: 2900 WingOakland, United StatesContact: Irene ChangTaking people
  • UPMC Children's Hospital of PittsburghPittsburgh, United StatesContact: Deepa RajanNot yet recruiting

About the trial

What the trial wants to find out

This is a global, open-label, Phase I/II, interventional trial in participants younger than 6 years of age with Mucopolysaccharidosis Type IIIB (MPS IIIB), designed to assess the safety and tolerability of JR-446, determine its pharmacodynamic effects, and explore its potential to demonstrate early clinical effects on disease-relevant outcomes.

The group in the trial

  • JR-446Treatment being tested

    Arm: 1

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Global, Open-Label, Phase I/II Trial, to Evaluate Safety, Tolerability, Pharmacodynamic and Preliminary Efficacy of JR-446 in Mucopolysaccharidosis Type IIIB (MPS IIIB)
Record updated
21 September 2026